Engineered immune cells take on relapsed leukemia in early trial
Disease control
Recruiting now
This study tests a new treatment called UCART22 for adults whose B-cell acute lymphoblastic leukemia (B-ALL) has come back or not responded to standard therapies. UCART22 uses donor immune cells that are specially designed to find and attack cancer cells carrying the CD22 marker.…
Phase: PHASE1, PHASE2 • Sponsor: Cellectis S.A. • Aim: Disease control
Last updated Jun 17, 2026 03:10 UTC